| |
 |
ARTICLES 
|
|
| Factoring outcomes in ovarian cancer |
| MA Bookman and RF Ozols |
|
JCO Feb 1 1996: 325–327.
[PDF]
|
 |
| Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children |
| SE Lipshultz |
|
JCO Feb 1 1996: 328–331.
[PDF]
|
|
| Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index |
| K Hellmann |
|
JCO Feb 1 1996: 332–333.
[PDF]
|
|
|
nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters |
| |
G Scambia, G Ferrandina, M Marone, P Benedetti Panici, C Giannitelli, M Piantelli, A Leone, and S Mancuso |
| |
JCO Feb 1 1996: 334–342.
[Abstract]
[PDF]
|
|
|
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy |
| |
E Pujade-Lauraine, JP Guastalla, N Colombo, P Devillier, E Francois, P Fumoleau, A Monnier, M Nooy, L Mignot, R Bugat, C Marques, M Mousseau, G Netter, F Maloisel, S Larbaoui, and M Brandely |
| |
JCO Feb 1 1996: 343–350.
[Abstract]
[PDF]
|
|
|
High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest |
| |
PF Conte, M Bruzzone, F Carnino, A Gadducci, R Algeri, A Bellini, F Boccardo, I Brunetti, E Catsafados, S Chiara, G Foglia, L Gallo, L Iskra, S Mammoliti, G Parodi, N Ragni, R Rosso, S Rugiati, and A Rubagotti |
| |
JCO Feb 1 1996: 351–356.
[Abstract]
[PDF]
|
|
|
High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study |
| |
SS Lentz, MF Brady, FJ Major, GC Reid, and JT Soper |
| |
JCO Feb 1 1996: 357–361.
[Abstract]
[PDF]
|
|
|
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin |
| |
LH Wexler, MP Andrich, D Venzon, SL Berg, L Weaver-McClure, CC Chen, V Dilsizian, N Avila, P Jarosinski, FM Balis, DG Poplack, and ME Horowitz |
| |
JCO Feb 1 1996: 362–372.
[Abstract]
[PDF]
|
|
|
Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy |
| |
BH Kushner, NK Cheung, MP LaQuaglia, PF Ambros, IM Ambros, MA Bonilla, WL Gerald, M Ladanyi, F Gilbert, NS Rosenfield, and SD Yeh |
| |
JCO Feb 1 1996: 373–381.
[Abstract]
[PDF]
|
|
|
High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study |
| |
DH Mahoney, Jr, D Strother, B Camitta, T Bowen, T Ghim, T Pick, D Wall, L Yu, JJ Shuster, and H Friedman |
| |
JCO Feb 1 1996: 382–388.
[Abstract]
[PDF]
|
|
|
Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group |
| |
PG Steinherz, PS Gaynon, JC Breneman, JM Cherlow, NJ Grossman, JH Kersey, HS Johnstone, HN Sather, ME Trigg, R Chappell, D Hammond, and WA Bleyer |
| |
JCO Feb 1 1996: 389–398.
[Abstract]
[PDF]
|
|
|
Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia |
| |
MV Relling, HH Mahmoud, CH Pui, JT Sandlund, GK Rivera, RC Ribeiro, WM Crist, and WE Evans |
| |
JCO Feb 1 1996: 399–404.
[Abstract]
[PDF]
|
|
|
Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma |
| |
D Meitar, SE Crawford, AW Rademaker, and SL Cohn |
| |
JCO Feb 1 1996: 405–414.
[Abstract]
[PDF]
|
|
|
Attitudes of 47 mothers of pediatric oncology patients toward genetic testing for cancer predisposition |
| |
AF Patenaude, L Basili, DL Fairclough, and FP Li |
| |
JCO Feb 1 1996: 415–421.
[Abstract]
[PDF]
|
|
|
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group |
| |
ME Trudeau, EA Eisenhauer, BP Higgins, F Letendre, WS Lofters, BD Norris, TA Vandenberg, F Delorme, and AM Muldal |
| |
JCO Feb 1 1996: 422–428.
[Abstract]
[PDF]
|
|
|
Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer |
| |
T Saarto, C Blomqvist, C Ehnholm, MR Taskinen, and I Elomaa |
| |
JCO Feb 1 1996: 429–433.
[Abstract]
[PDF]
|
|
|
Effect of tamoxifen on endometrial proliferation |
| |
A Decensi, V Fontana, S Bruno, C Gustavino, B Gatteschi, and A Costa |
| |
JCO Feb 1 1996: 434–440.
[Abstract]
[PDF]
|
|
|
Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial |
| |
J Pont, W Albrecht, G Postner, F Sellner, K Angel, and W Holtl |
| |
JCO Feb 1 1996: 441–448.
[Abstract]
[PDF]
|
|
|
Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma |
| |
K Wallner, J Roy, and L Harrison |
| |
JCO Feb 1 1996: 449–453.
[Abstract]
[PDF]
|
|
|
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center |
| |
HS Puc, R Heelan, M Mazumdar, H Herr, J Scheinfeld, V Vlamis, DF Bajorin, GJ Bosl, P Mencel, and RJ Motzer |
| |
JCO Feb 1 1996: 454–460.
[Abstract]
[PDF]
|
|
|
Prognostic significance of the microvascular count in colorectal cancer |
| |
G Lindmark, B Gerdin, C Sundberg, L Pahlman, R Bergstrom, and B Glimelius |
| |
JCO Feb 1 1996: 461–466.
[Abstract]
[PDF]
|
|
|
Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma [published erratum appears in J Clin Oncol 1996 Aug;14(8):2411] |
| |
O Feugeas, N Guriec, A Babin-Boilletot, L Marcellin, P Simon, S Babin, A Thyss, P Hofman, P Terrier, C Kalifa, M Brunat-Mentigny, LM Patricot, and F Oberling |
| |
JCO Feb 1 1996: 467–472.
[Abstract]
[PDF]
|
|
|
Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: implications for management |
| |
MJ Heslin, J Woodruff, and MF Brennan |
| |
JCO Feb 1 1996: 473–478.
[Abstract]
[PDF]
|
|
|
Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study |
| |
DL Fraker, HR Alexander, M Andrich, and SA Rosenberg |
| |
JCO Feb 1 1996: 479–489.
[Abstract]
[PDF]
|
|
|
The value of high-dose methotrexate-based neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone |
| |
SJ Ham, HJ Hoekstra, WT van der Graaf, WA Kamps, WM Molenaar, and H Schraffordt Koops |
| |
JCO Feb 1 1996: 490–496.
[Abstract]
[PDF]
|
|
|
Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers |
| |
M Nishio, T Koshikawa, T Kuroishi, M Suyama, K Uchida, Y Takagi, O Washimi, T Sugiura, Y Ariyoshi, T Takahashi, R Ueda, and T Takahashi |
| |
JCO Feb 1 1996: 497–502.
[Abstract]
[PDF]
|
|
|
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy |
| |
R Perez-Soler, FV Fossella, BS Glisson, JS Lee, WK Murphy, DM Shin, BL Kemp, JJ Lee, J Kane, RA Robinson, SM Lippman, JM Kurie, MH Huber, MN Raber, and WK Hong |
| |
JCO Feb 1 1996: 503–513.
[Abstract]
[PDF]
|
|
|
Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte |
| |
P Solal-Celigny, P Brice, N Brousse, H Caspard, Y Bastion, C Haioun, A Bosly, H Tilly, D Bordessoule, C Sebban, JL Harousseau, P Morel, B Dupas, F Plassart, N Vasile, N Fort, and M Leporrier |
| |
JCO Feb 1 1996: 514–519.
[Abstract]
[PDF]
|
|
|
Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy |
| |
JM Vose, JE Anderson, PJ Bierman, FR Appelbaum, JR Anderson, L Garrison, ME Lebsack, and JO Armitage |
| |
JCO Feb 1 1996: 520–526.
[Abstract]
[PDF]
|
|
|
Vinblastine, bleomycin, and methotrexate chemotherapy plus extended- field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience |
| |
PG Gobbi, C Pieresca, A Frassoldati, M Carotenuto, N Di Renzo, A La Sala, R Berte, P Avanzini, M Federico, V Silingardi, and E Ascari |
| |
JCO Feb 1 1996: 527–533.
[Abstract]
[PDF]
|
|
|
High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study |
| |
M Martelli, M Vignetti, PL Zinzani, F Gherlinzoni, G Meloni, M Fiacchini, V De Sanctis, G Papa, MF Martelli, F Calabresi, S Tura, and F Mandelli |
| |
JCO Feb 1 1996: 534–542.
[Abstract]
[PDF]
|
|
|
No effect of 96-hour paclitaxel infusion in patients with relapsed non- Hodgkin's lymphoma refractory to a 3-hour infusion schedule |
| |
A Younes, JP Ayoub, FB Hagemeister, P McLaughlin, A Sarris, MA Rodriguez, F Swan, Jr, JE Romaguera, J Martin, and F Cabanillas |
| |
JCO Feb 1 1996: 543–548.
[Abstract]
[PDF]
|
|
|
Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy |
| |
JU Rijlaarsdam, J Toonstra, OW Meijer, EM Noordijk, and R Willemze |
| |
JCO Feb 1 1996: 549–555.
[Abstract]
[PDF]
|
|
|
Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06 |
| |
C Schultz, C Scott, W Sherman, B Donahue, J Fields, K Murray, B Fisher, R Abrams, and J Meis-Kindblom |
| |
JCO Feb 1 1996: 556–564.
[Abstract]
[PDF]
|
|
|
Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma |
| |
LB Travis, J Weeks, RE Curtis, JT Chaffey, M Stovall, PM Banks, and JD Boice, Jr |
| |
JCO Feb 1 1996: 565–571.
[Abstract]
[PDF]
|
|
|
Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease |
| |
JL Gajewski, GL Phillips, KA Sobocinski, JO Armitage, RP Gale, RE Champlin, RH Herzig, DD Hurd, S Jagannath, JP Klein, HM Lazarus, PL McCarthy, Jr, S Pavlovsky, FB Peterson, PA Rowlings, JA Russell, SM Silver, JM Vose, PH Wiernik, MM Bortin, and MM Horowitz |
| |
JCO Feb 1 1996: 572–578.
[Abstract]
[PDF]
|
|
|
Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease |
| |
R Miralbell, S Bieri, B Mermillod, C Helg, G Sancho, B Pastoors, A Keller, JM Kurtz, and B Chapuis |
| |
JCO Feb 1 1996: 579–585.
[Abstract]
[PDF]
|
|
|
Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma |
| |
R Pettengell, JA Radford, GR Morgenstern, JH Scarffe, M Harris, PJ Woll, DP Deakin, D Ryder, PM Wilkinson, and D Crowther |
| |
JCO Feb 1 1996: 586–592.
[Abstract]
[PDF]
|
|
|
Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type |
| |
B Schlegelberger, T Zwingers, K Hohenadel, D Henne-Bruns, N Schmitz, T Haferlach, C Tirier, H Bartels, R Sonnen, and R Kuse |
| |
JCO Feb 1 1996: 593–599.
[Abstract]
[PDF]
|
|
|
Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas |
| |
MJ Glantz, H Choy, CM Kearns, BF Cole, P Mills, EG Zuhowski, S Saris, CH Rhodes, E Stopa, and MJ Egorin |
| |
JCO Feb 1 1996: 600–609.
[Abstract]
[PDF]
|
|
|
Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer |
| |
DJ Boote, IF Dennis, PR Twentyman, RJ Osborne, C Laburte, S Hensel, JF Smyth, MH Brampton, and NM Bleehen |
| |
JCO Feb 1 1996: 610–618.
[Abstract]
[PDF]
|
|
|
Randomized placebo-controlled trial of granulocyte-macrophage colony- stimulating factor in patients with chemotherapy-related febrile neutropenia |
| |
E Vellenga, CA Uyl-de Groot, R de Wit, HJ Keizer, B Lowenberg, MA ten Haaft, TJ de Witte, CA Verhagen, GJ Stoter, FF Rutten, NH Mulder, WM Smid, and EG de Vries |
| |
JCO Feb 1 1996: 619–627.
[Abstract]
[PDF]
|
|
|
Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy |
| |
M Bregni, S Siena, M Di Nicola, A Dodero, F Peccatori, F Ravagnani, G Danesini, A Laffranchi, G Bonadonna, and AM Gianni |
| |
JCO Feb 1 1996: 628–635.
[Abstract]
[PDF]
|
|
|
Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia |
| |
JY Blay, F Chauvin, A Le Cesne, B Anglaret, D Bouhour, C Lasset, G Freyer, T Philip, and P Biron |
| |
JCO Feb 1 1996: 636–643.
[Abstract]
[PDF]
|
|
|
Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained |
| |
R de Wit, PI Schmitz, J Verweij, M de Boer-Dennert, PH de Mulder, AS Planting, ME van der Burg, and G Stoter |
| |
JCO Feb 1 1996: 644–651.
[Abstract]
[PDF]
|
|
|
Inferior vena cava filters in cancer patients: indications and outcome |
| |
RE Schwarz, AM Marrero, KC Conlon, and M Burt |
| |
JCO Feb 1 1996: 652–657.
[Abstract]
[PDF]
|
|
| Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat |
| J Aisner |
|
JCO Feb 1 1996: 658–665.
[PDF]
|
|
| Funding for clinical (patient-oriented) oncology research: current status and recommendations for improvement. American Society of Clinical Oncology |
|
|
JCO Feb 1 1996: 666–670.
[PDF]
|
|
|
Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology |
| |
|
| |
JCO Feb 1 1996: 671–679.
[Abstract]
[PDF]
|
|
| Defining new standards for adjuvant therapy of testis cancer: a reply |
| RJ Motzer, J Sheinfeld, and H Herr |
|
JCO Feb 1 1996: 680a.
[PDF]
|
|
| Uniform criteria for childhood acute lymphoblastic leukemia risk classification |
| M Smith, A Bleyer, W Crist, S Murphy, and SE Sallan |
|
JCO Feb 1 1996: 680b–681.
[PDF]
|
|
| DNA repair and the risk of secondary leukemias |
| SL Gerson |
|
JCO Feb 1 1996: 681–682.
[PDF]
|
|
| Bone marrow biopsy for staging Hodgkin's lymphoma: the value of bilateral or unilateral trephine biopsy |
| M Luoni, S Fava, and P Declich |
|
JCO Feb 1 1996: 682–683.
[PDF]
|
|
| Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrence |
| SS Bielack, B Kempf-Bielack, and K Winkler |
|
JCO Feb 1 1996: 683–684.
[PDF]
|
|
| Ethical questions on the testicular seminoma study |
| P Narasimhan and J Kalra |
|
JCO Feb 1 1996: 684a.
[PDF]
|
|
| High-dose chemotherapy for metastatic breast cancer |
| A Recht |
|
JCO Feb 1 1996: 684b–685.
[PDF]
|
|
| Dose-intensive metastatic breast cancer chemotherapy |
| MH Cohen |
|
JCO Feb 1 1996: 685–686.
[PDF]
|
|
| High-dose chemotherapy for breast cancer |
| CH Spiridonidis, LR Laufman, V Rhodes, and J Jones |
|
JCO Feb 1 1996: 686a.
[PDF]
|
|
| Risk stratification for high-dose chemotherapy in metastatic breast cancer |
| M Subar |
|
JCO Feb 1 1996: 686b–687.
[PDF]
|
|
| Cost-effectiveness: let's get "real" |
| SR Lemkin |
|
JCO Feb 1 1996: 687–688.
[PDF]
|
|
| Tumor necrosis factor: is it a breakthrough? |
| FO Stephens |
|
JCO Feb 1 1996: 688–689.
[PDF]
|
|
| Megestrol acetate-induced adrenal suppression |
| CL Loprinzi, R Fonseca, and MD Jensen |
|
JCO Feb 1 1996: 689.
[PDF]
|
|
